Tomoh Masaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tomoh Masaki has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Haruaki Ninomiya
Department of Structural Analysis, National Cardiovascular Research Institute, 5-7-1 Fujishirodai, Suita, Osaka 565, Japan
7 shared publicationsTatsuya Sawamura
Department of Structural Analysis, National Cardiovascular Research Institute, 5-7-1 Fujishirodai, Suita, Osaka 565, Japan
4 shared publications- Aiji Sakamoto
Laboratory of Vascular Biology, National Cerebral and Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan
2 shared publications Ken-Ichiro Kikuta
Department of Pharmacology, and Neurosurgery, Faculty of Medicine, Kyoto University, Kyoto, Japan
2 shared publicationsShigekazu Itokawa
Departments of *Pharmacology and §Geriatric Medicine, Faculty of Medicine, Kyoto University, Kyoto 606 Japan; †Department of Bioscience, National Cardiovascular Center Research Institute, Suita, Osaka 565-8565, Japan; and ‡Department of Molecular Pathophysiology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871, Japan
2 shared publicationsSoichi Miwa
2 shared publications
Latest Publications
- 13 August 1999
- Published by Elsevier in Brain Research
- Vol. 838 (1-2) , 158-165
Neuron-specific expression of cationic amino acid transporter 3 in the adult rat brain
- 13 August 1999
- Published by Elsevier in Brain Research
- Vol. 838 (1-2) , 158-165
Neuron-specific expression of cationic amino acid transporter 3 in the adult rat brain
- 1 June 1999
- Published by Elsevier in European Journal of Pharmacology
- Vol. 375 (1-3) , 133-138
Subcellular mechanisms of endothelin action in vascular system
- 1 June 1999
- Published by Elsevier in European Journal of Pharmacology
- Vol. 375 (1-3) , 133-138
Subcellular mechanisms of endothelin action in vascular system
- 1 March 1999
- Published by Annual Reviews in Annual Review of Physiology
- Vol. 61 (1) , 391-415
PATHOPHYSIOLOGY OF ENDOTHELIN IN THE CARDIOVASCULAR SYSTEM
▪ Abstract In this article, we review the basic pharmacological and biochemical features of endothelin and the pathophysiological roles of endothelin in cardiovascular diseases. Development of receptor antagonists has accelerated the pace of investigations into the pathophysiological roles of endogenous endothelin-1 in various diseases, e.g. chronic heart failure, renal diseases, hypertension, cerebral vasospasm, and pulmonary hypertension. In chronic heart failure, the expression of endothelin-1 and its receptors in cardiomyocytes is increased, and treatment with an endothelin receptor antagonist improves survival and cardiac function. Endothelin receptor antagonists also improve other cardiovascular diseases. These results suggest that the interference with endothelin pathway either by receptor blockade or by inhibition of endothelin converting enzyme may provide novel therapeutic drugs strategies for multiple disease states.
- 1 March 1999
- Published by Annual Reviews in Annual Review of Physiology
- Vol. 61 (1) , 391-415
PATHOPHYSIOLOGY OF ENDOTHELIN IN THE CARDIOVASCULAR SYSTEM
▪ Abstract In this article, we review the basic pharmacological and biochemical features of endothelin and the pathophysiological roles of endothelin in cardiovascular diseases. Development of receptor antagonists has accelerated the pace of investigations into the pathophysiological roles of endogenous endothelin-1 in various diseases, e.g. chronic heart failure, renal diseases, hypertension, cerebral vasospasm, and pulmonary hypertension. In chronic heart failure, the expression of endothelin-1 and its receptors in cardiomyocytes is increased, and treatment with an endothelin receptor antagonist improves survival and cardiac function. Endothelin receptor antagonists also improve other cardiovascular diseases. These results suggest that the interference with endothelin pathway either by receptor blockade or by inhibition of endothelin converting enzyme may provide novel therapeutic drugs strategies for multiple disease states.
- 1 February 1999
- Published by Wiley in British Journal of Pharmacology
- Vol. 126 (4) , 893-902
Selective activation of excitation-contraction coupling pathways by ETA and ETB receptors in guinea-pig tracheal smooth muscle
1. Signalling events responsible for endothelin(A) (ET(A)) and ET(B) receptor-induced contraction were examined in epithelium-denuded guinea-pig tracheal smooth muscle strips. Selective stimulation of each subtype was achieved by a combination of ET-1 (100 nM) and ET(A) and ET(B) receptor-selective antagonists, BQ-123 (10 microM) and BQ-788 (3 microM), respectively. 2. Both ET(A) and ET(B) receptors induced long-lasting contraction that was totally dependent on Ca2+ influx. Stimulation of ET(A) receptor induced both transient and sustained (Ca2+)i increases whereas that of ET(B) receptor induced only a sustained increase. Suppression of the transient (Ca2+)i increase by U73122 (3 microM) did not affect the ET(A)-induced sustained (Ca2+)i increase and tension development. Stimulation of ET(A) receptor, but not ET(B), induced phosphoinositide breakdown and protein kinase C (PKC). The activated PKC contributed to the contraction by increasing the Ca2+ sensitivity of the contractile apparatus. 3. Thus, ET(A) receptor is coupled both with phospholipase C/Ca2+/PKC signalling and Ca2+ influx pathways whereas ET(B) receptor was coupled only with the latter. 4. Stimulation of ET(B) receptor, but not ET(A), caused membrane depolarization measured with a fluorescent indicator, bis-(1,3 dibutylbarbituric acid)-trimethine oxonol. Both nifedipine (1 microM) and verapamil (10 microM) abolished ET(B)-induced Ca2+ influx and contraction, while they barely affected ET(A)-induced responses. 5. Therefore, the Ca2+ influx pathways activated by each subtype appeared to be completely different; ET(A) and ET(B) receptors opens voltage-independent Ca2+ channels and L-type voltage-dependent Ca2+ channels, respectively.
- 1 February 1999
- Published by Wiley in British Journal of Pharmacology
- Vol. 126 (4) , 893-902
Selective activation of excitation-contraction coupling pathways by ETA and ETB receptors in guinea-pig tracheal smooth muscle
1. Signalling events responsible for endothelin(A) (ET(A)) and ET(B) receptor-induced contraction were examined in epithelium-denuded guinea-pig tracheal smooth muscle strips. Selective stimulation of each subtype was achieved by a combination of ET-1 (100 nM) and ET(A) and ET(B) receptor-selective antagonists, BQ-123 (10 microM) and BQ-788 (3 microM), respectively. 2. Both ET(A) and ET(B) receptors induced long-lasting contraction that was totally dependent on Ca2+ influx. Stimulation of ET(A) receptor induced both transient and sustained (Ca2+)i increases whereas that of ET(B) receptor induced only a sustained increase. Suppression of the transient (Ca2+)i increase by U73122 (3 microM) did not affect the ET(A)-induced sustained (Ca2+)i increase and tension development. Stimulation of ET(A) receptor, but not ET(B), induced phosphoinositide breakdown and protein kinase C (PKC). The activated PKC contributed to the contraction by increasing the Ca2+ sensitivity of the contractile apparatus. 3. Thus, ET(A) receptor is coupled both with phospholipase C/Ca2+/PKC signalling and Ca2+ influx pathways whereas ET(B) receptor was coupled only with the latter. 4. Stimulation of ET(B) receptor, but not ET(A), caused membrane depolarization measured with a fluorescent indicator, bis-(1,3 dibutylbarbituric acid)-trimethine oxonol. Both nifedipine (1 microM) and verapamil (10 microM) abolished ET(B)-induced Ca2+ influx and contraction, while they barely affected ET(A)-induced responses. 5. Therefore, the Ca2+ influx pathways activated by each subtype appeared to be completely different; ET(A) and ET(B) receptors opens voltage-independent Ca2+ channels and L-type voltage-dependent Ca2+ channels, respectively.
- 30 November 1998
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 83 (11) , 1088-1096
High-Affinity Arginine Transport of Bovine Aortic Endothelial Cells Is Impaired by Lysophosphatidylcholine
—The mechanisms of endothelial dysfunction characterized by the impaired nitric oxide (NO) release have not yet been clarified. Because the phenomenon is mimicked in vitro by the application of oxidized LDL and its major lipid constituent, lysophosphatidylcholine (LPC), we analyzed their effects on the arginine-NO system, especially on the arginine transport system. LPC inhibited NO release induced by ADP in cultured bovine aortic endothelial cells. The inhibition was attenuated by the excess amount of extracellular arginine. LPC was found to inhibit the arginine transport in bovine aortic endothelial cells, which is mediated by high- and low-affinity components. LPC predominantly impaired the high-affinity component. In the presence of a high concentration of arginine, LPC showed apparently no inhibition of arginine transport, because the low-affinity transporter compensated for the activity. Taken together, the impairment of the high-affinity transport system might account for the inhibition of NO release by LPC. LPC also inhibited arginine transport in the intima of intact bovine aorta. Furthermore, LPC inhibited the activity of the high-affinity arginine transporter in endothelial cells, in the cationic amino acid transporter-1 expressed in COS-7 cells. The activity of cationic amino acid transporter-1 might be important for the prevention of endothelial dysfunction.
- 30 November 1998
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 83 (11) , 1088-1096
High-Affinity Arginine Transport of Bovine Aortic Endothelial Cells Is Impaired by Lysophosphatidylcholine
—The mechanisms of endothelial dysfunction characterized by the impaired nitric oxide (NO) release have not yet been clarified. Because the phenomenon is mimicked in vitro by the application of oxidized LDL and its major lipid constituent, lysophosphatidylcholine (LPC), we analyzed their effects on the arginine-NO system, especially on the arginine transport system. LPC inhibited NO release induced by ADP in cultured bovine aortic endothelial cells. The inhibition was attenuated by the excess amount of extracellular arginine. LPC was found to inhibit the arginine transport in bovine aortic endothelial cells, which is mediated by high- and low-affinity components. LPC predominantly impaired the high-affinity component. In the presence of a high concentration of arginine, LPC showed apparently no inhibition of arginine transport, because the low-affinity transporter compensated for the activity. Taken together, the impairment of the high-affinity transport system might account for the inhibition of NO release by LPC. LPC also inhibited arginine transport in the intima of intact bovine aorta. Furthermore, LPC inhibited the activity of the high-affinity arginine transporter in endothelial cells, in the cationic amino acid transporter-1 expressed in COS-7 cells. The activity of cationic amino acid transporter-1 might be important for the prevention of endothelial dysfunction.
- 4 August 1998
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 95 (16) , 9535-9540
Lectin-like oxidized low-density lipoprotein receptor 1 mediates phagocytosis of aged/apoptotic cells in endothelial cells
Recognition of the exposure of phosphatidylserine (PS) on the outer surface of plasma membrane has been implicated in the phagocytosis of aged/apoptotic cells. Because oxidized low-density lipoprotein (OxLDL) has been reported to block the phagocytosis, here we examined whether lectin-like OxLDL receptor 1 (LOX-1), the OxLDL receptor in endothelial cells, mediates phagocytosis of aged/apoptotic cells by endothelial cells. Cultured bovine aortic endothelial cells (BAE) and Chinese hamster ovary (CHO) cells expressing bovine LOX-1 (BLOX-1-CHO), but not wild-type CHO-K1 cells, bound aged red blood cells (RBC) and apoptotic cells, which were further phagocytosed. The binding of aged RBC and the phagocytosis of apoptotic cells were inhibited by OxLDL, acetyl LDL, and other LOX-1 ligands in both BAE and BLOX-1-CHO. mAb against LOX-1 blocked the binding of aged RBC to BAE, suggesting a role for LOX-1 in the recognition of aged cells. The recombinant soluble LOX-1 inhibited the interactions of aged/apoptotic cells with both BLOX-1-CHO and BAE and distinguished aged RBC from native RBC and apoptotic cells from native cells. PS liposome inhibited these LOX-1-mediated interactions with aged/apoptotic cells, suggesting LOX-1 recognizes PS of the apoptotic cells. PS exposed on the surface of apoptotic cells is known to be procoagulant. Accordingly, increased OxLDL may be one of the reasons for enhanced coagulation in atherosclerosis, inhibiting the removal of apoptotic cells.
- 4 August 1998
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 95 (16) , 9535-9540
Lectin-like oxidized low-density lipoprotein receptor 1 mediates phagocytosis of aged/apoptotic cells in endothelial cells
Recognition of the exposure of phosphatidylserine (PS) on the outer surface of plasma membrane has been implicated in the phagocytosis of aged/apoptotic cells. Because oxidized low-density lipoprotein (OxLDL) has been reported to block the phagocytosis, here we examined whether lectin-like OxLDL receptor 1 (LOX-1), the OxLDL receptor in endothelial cells, mediates phagocytosis of aged/apoptotic cells by endothelial cells. Cultured bovine aortic endothelial cells (BAE) and Chinese hamster ovary (CHO) cells expressing bovine LOX-1 (BLOX-1-CHO), but not wild-type CHO-K1 cells, bound aged red blood cells (RBC) and apoptotic cells, which were further phagocytosed. The binding of aged RBC and the phagocytosis of apoptotic cells were inhibited by OxLDL, acetyl LDL, and other LOX-1 ligands in both BAE and BLOX-1-CHO. mAb against LOX-1 blocked the binding of aged RBC to BAE, suggesting a role for LOX-1 in the recognition of aged cells. The recombinant soluble LOX-1 inhibited the interactions of aged/apoptotic cells with both BLOX-1-CHO and BAE and distinguished aged RBC from native RBC and apoptotic cells from native cells. PS liposome inhibited these LOX-1-mediated interactions with aged/apoptotic cells, suggesting LOX-1 recognizes PS of the apoptotic cells. PS exposed on the surface of apoptotic cells is known to be procoagulant. Accordingly, increased OxLDL may be one of the reasons for enhanced coagulation in atherosclerosis, inhibiting the removal of apoptotic cells.
- 31 October 1997
- Published by Elsevier in Atherosclerosis
- Vol. 134 (1) , 359
4.P.300 Inducible expression of LOX-1, a novel receptor for oxidized low density lipoprotein, in vascular endothelial cells
- 31 October 1997
- Published by Elsevier in Atherosclerosis
- Vol. 134 (1) , 359
4.P.300 Inducible expression of LOX-1, a novel receptor for oxidized low density lipoprotein, in vascular endothelial cells
- Open Access
- 1 August 1997
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 272 (34) , 21589-21596
Palmitoylation of Human EndothelinB
- 1 August 1997
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 272 (34) , 21589-21596
Open AccessPalmitoylation of Human EndothelinB
- 19 May 1997
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 234 (2) , 526-530
Bromodeoxyuridine-Induced Expression of EndothelinAin A375 Human Melanoma Cells
- 19 May 1997
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 234 (2) , 526-530
Bromodeoxyuridine-Induced Expression of EndothelinAin A375 Human Melanoma Cells